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Unfortunately, these late occlusions have been found to
occur in 20% to 30% of the vein grafts in the first postop-
erative year.1-5 Vein graft surveillance is increasingly being
used as a means of identifying failing grafts during the first
postoperative year.6-8 Currently, surveillance programs
usually consist of clinical follow-up with measurement of
the ankle-brachial index (ABI) or color-guided duplex
scan examination of the bypass graft. The best criterion for
detecting a graft stenosis in a surveillance program is the
peak systolic velocity (PSV) ratio available from duplex
scan examination, whereas the addition of ABI to the PSV
ratio does not increase the area under the receiver operat-
ing characteristic curve, implying that the diagnostic per-
formance will not improve.9
An overall gain in the long-term patency of grafts
undergoing duplex scan surveillance has been demon-
strated in a randomized trial.10 It is, however, unclear
whether the gain in effects (ie, avoiding an amputation)
justifies the expense of such a program. The TransAtlantic
Inter-Society Consensus Working group advised further
research on this issue.11 Early repair of stenosed grafts is a
relatively simple and inexpensive procedure compared
Early occlusions of infrainguinal autologous vein
bypass grafts are mostly caused by thrombosis occurring
during the first few weeks postoperatively, whereas late
occlusions are mostly caused by stenotic lesions.1
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Purpose: In this study we assessed the costs and clinical outcomes of duplex scan surveillance during the first year after
infrainguinal autologous vein bypass grafting surgery and compared duplex scan surveillance, ankle-brachial index sur-
veillance, and clinical follow-up.
Methods: In a clinical study, 293 patients (mean age, 70.1 years; 58.7% men) with peripheral arterial disease were
observed in a duplex scan surveillance program after infrainguinal autologous vein bypass grafting surgery. Costs were
calculated from the health care perspective for surveillance and subsequent interventions from 30 days to 1 year post-
operatively. All costs are presented in 1995 US dollars per patient. In a simulation model, we estimated the costs and
amputations of duplex scan surveillance, ankle-brachial index surveillance, and clinical follow-up conditional on the
indication for surgery. The main outcome measure was the incremental cost per major amputation per patient avoided
during the first postoperative year.
Results: Duplex scan surveillance was the least expensive ($2823) and resulted in the fewest major amputations (17 per
1000 patients examined), compared with ankle-brachial index surveillance ($5411 and 77 amputations per 1000
patients) and clinical follow-up ($5072 and 77 amputations per 1000 patients). In patients treated for critical limb
ischemia, duplex scan surveillance was the least expensive ($2974) and resulted in the fewest major amputations (19
per 1000 patients). Under all surveillance programs, 13 major amputations per 1000 patients treated for intermittent
claudication were performed, and clinical follow-up had the lowest costs ($1577). In a sensitivity analysis that assumed
that duplex scan surveillance could have avoided six major amputations per 1000 patients treated for intermittent clau-
dication compared with the other programs, duplex scan surveillance had an incremental cost of $80,708 per major
amputation per patient avoided compared with clinical follow-up. 
Conclusion: Duplex scan surveillance is highly effective for patients treated for critical limb ischemia, leading to a reduction
of major amputations and consequently to a reduction in costs compared with other surveillance programs. In patients
treated for intermittent claudication, the evidence supporting duplex scan surveillance is less firm, but if duplex scan can
avoid six major amputations per 1000 patients examined, the incremental costs are justified. (J Vasc Surg 2001;33:123-30.)
with an amputation of the limb after a failed graft because
of an uncorrected high-grade stenosis. Amputation clearly
has a major impact on the health-related quality of life of
the patient12,13 and involves high costs for hospitalization
and rehabilitation.14,15 The costs of duplex scan surveil-
lance may be justified if there is an overall gain in effects,
which could also lead to an overall cost-reduction in the
follow-up of these patients.
The objective of our study was to assess the costs and
clinical outcomes of duplex scan surveillance during the
first year after infrainguinal autologous vein bypass graft-
ing surgery and to compare duplex scan surveillance, ABI
surveillance, and clinical follow-up.
METHODS
Clinical study. In a prospective multicenter study, 293
patients with peripheral arterial disease underwent infrain-
guinal autologous vein bypass grafting surgery and were
observed in a duplex scan surveillance program. The three
participating centers were Catharina Hospital, Eindhoven
(176 grafts), Sint Antonius Hospital, Nieuwegein (56
grafts), and the University Hospital Maastricht (61 grafts).
Between June 1993 and September 1995, 340 patients
underwent bypass grafting surgery, but 47 patients did not
meet the inclusion criteria of the study because of death
within 30 days after surgery (n = 6), irreversible graft occlu-
sion within 30 days after surgery (n = 20), amputation
within 30 days after surgery (n = 7), or no duplex scan sur-
veillance being performed (n = 14). Follow-up ended in
September 1996, and only one graft per patient was con-
sidered. The clinical study was approved by the Institutional
Review Board, and all patients gave informed consent.
The duplex scan surveillance program started between 4
and 6 weeks after the initial bypass grafting procedure with a
color flow duplex ultrasound scanning examination of the
graft and its adjacent inflow and outflow tracts.
Subsequently, color flow duplex ultrasound scanning was
performed at 3, 6, 9, and 12 months after the procedure.
Additionally, an ABI in rest and during reactive hyperemia
were performed at the same time points as duplex scan
examination. An intra-arterial digital subtraction angiogra-
phy (DSA) (Catharina Hospital and Sint Antonius Hospital)
or an intravenous DSA (University Hospital Maastricht) was
indicated when one of these was present: (1) symptoms of
intermittent claudication or rest pain; (2) a drop in ABI of
more than 0.15; (3) visualization of more than 30% stenosis
on duplex scan; (4) a PSV-ratio more than 2.0; (5) PSV-graft
less than 45 cm/s; or (6) end-diastolic velocity more than 20
cm/s (suggests the presence of a stenosis more than 70%16).
Surgical revascularization or angioplasty was indicated when
a stenosis ≥ 70% was present, and a 50% to 70% stenosis was
followed with another color flow duplex scan examination 6
weeks later as a means of detecting progression of disease.
Only in the absence of progression of the lesion was the 3-
month surveillance program resumed until 1 year after the
first detection of the lesion. Bypass grafts with less than 50%
stenosis were considered normal grafts. Angioplasty was
indicated when the stenosis was no longer than 1 cm and
located distal to the anastomosis or in the middle of the
graft; otherwise, surgical revascularization was performed.
Color flow duplex scanning was performed with an
Acuson 128 XP/10 (Catharina Hospital) (Acuson,
Mountain View, Calif), a Hewlett-Packard Sonos 2000
(Sint Antonius Hospital), and a Hewlett-Packard Sonos
1000 (University Hospital Maastricht) (Hewlett-Packard,
Palo Alto, Calif), all with a 7.5-MHz transducer except for
deep located vein grafts for which a 5.0-MHz transducer
was used. The settings of the duplex scan machines used
in this study were similar. The systolic ankle blood pres-
sure was measured twice with the patient lying supine with
a 15-cm wide blood pressure cuff, and the systolic brachial
blood pressure was measured at both arms. The mean of
the two ankle pressures was divided by the highest of the
brachial pressures to determine the ABI. ABI during reac-
tive hyperemia was measured after 50–mm Hg suprasys-
tolic thigh cuff inflation during a 3-minute period. 
More detailed information on the clinical study and sur-
veillance results can be found in articles by Idu et al.9,17,18
Cost data. Costs were estimated from the cost account-
ing system of Catharina Hospital. In addition, for duplex
ultrasound scanning examination, ABI, and DSA, a detailed
microcosting analysis of personnel and capacity was per-
formed both in the Catharina Hospital and the University
Hospital Maastricht. All costs were calculated from the
health care perspective and included personnel (including
social security and overtime), equipment, disposables, hos-
pitalization, and overhead. Overhead costs consisted of a
percentage of the total costs for general administration and
the board of directors; an amount per square meter for use
of the building, security service, inventory, and energy; an
amount for general personnel costs, special regulations, and
personnel services weighted by the number of working
hours; and an amount for personnel administration
weighted by the number of employees.
Actual costs were calculated for duplex scan exami-
nation, ABI, DSA, outpatient visits, and interventions
related to peripheral arterial disease of the studied limb
(Table I). These interventions were surgical revascular-
ization of the graft, thrombolysis, angioplasty, major
amputations, and minor amputations (toe or forefoot).
The hospitalization costs and procedure costs of minor
amputations were assumed to be half the costs of a major
amputation, except for the material cost during the pro-
cedure, which was assumed to be the same. Costs for
rehabilitation of major amputations were estimated, and
costs of rehabilitation for minor amputations were
assumed to be negligible. Because all major amputations
were above the knee, the rehabilitation costs were esti-
mated for amputations above the knee only. Costs for
thrombolysis were available from literature data. Costs of
complications related to the performed procedures and
intercurrent illness were not considered. All costs were
calculated in 1995 Dutch guilders and subsequently con-
verted to US dollars by using the mean exchange rate for
1995 (1 US dollar = 1.61 guilders; Central Bureau of
Statistics, The Netherlands).
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Data analysis and simulation model. On the basis of
the clinical description of the Rutherford classification,19
we subdivided the patients into those treated for critical
limb ischemia (n = 215) and those treated for intermittent
claudication (n = 78). The average costs per patient for
duplex scan surveillance and subsequent interventions
were calculated for the period between 30 days and 1 year
after surgery for the entire patient group and defined sub-
groups. Costs included duplex scan examinations, outpa-
tient visits, DSAs, interventions related to peripheral
arterial disease, and repeat interventions for failed inter-
ventions, if performed. Angioplasties, surgical revascular-
izations, and thrombolyses of the graft were included in
the proportion performed in the clinical study, and on the
basis of these proportions, the number of angioplasties,
surgical revascularizations, and thrombolyses were esti-
mated for ABI surveillance and clinical follow-up. The
cost analysis of the duplex scan surveillance program did
not include ABI measurements. Because the number of
outpatient visits was not recorded, we assumed that the
number of outpatient visits equaled the number of duplex
scan examinations during the first year. Because of logisti-
cal reasons only, 12 patients had their first duplex scan
examination before the official starting point of 30 days
after surgery, and the costs of these duplex scan examina-
tions were included.
A simulation model was developed as a means of esti-
mating the costs and clinical outcomes of ABI surveillance
and clinical follow-up without surveillance. In this model,
we assumed that patients who did not undergo a reinter-
vention or amputation during the first postoperative year in
the clinical study (ie, with duplex scan surveillance) had the
same course in the ABI surveillance program and under
clinical follow-up. In essence, this assumes that duplex scan
surveillance is the most sensitive means of identifying
lesions of the three programs. For patients who had an
intervention in the clinical study during the first postoper-
ative year, the number of amputations, angioplasties, surgi-
cal revascularizations, and thrombolyses of the graft for
clinical follow-up were estimated by the use of probabilities
available from literature data.6 On the basis of the data
extracted from the study by Bergamini et al,6 we calculated
relative risks for duplex scan surveillance versus clinical fol-
low-up for major amputations performed and interven-
tions performed. The probabilities under clinical follow-up
were calculated by multiplying the probability under
duplex scan surveillance by the relative risk (Table II). For
patients who had an intervention in the clinical study dur-
ing the first postoperative year, we assumed for ABI sur-
veillance that a drop of more than 0.20 in ABI compared
with the preceding ABI would lead to the same medical
advice and intervention as when duplex scan surveillance
was performed. If a drop of 0.20 or less in ABI was noted
compared with the preceding ABI, we assumed that the
course would be the same as having clinical follow-up. A
scheme of the simulation model is presented in Fig 1.
The follow-up scheme of the ABI surveillance was the
same as the follow-up scheme of the duplex scan surveil-
lance during the first postoperative year. For clinical follow-
up, we assumed that patients had, on average, four outpa-
tient visits during the first year, and patients who died or
underwent a major amputation during the first year had, on
average, two outpatient visits. The numbers of DSAs per-
formed under duplex scan surveillance equaled the number
of DSAs on indication performed in the clinical study. For
ABI surveillance and clinical follow-up, we estimated the
number of DSAs that would have been performed among
the studied patients had they not been examined with
duplex scan but instead examined with, respectively, ABI
surveillance or clinical follow-up. For ABI surveillance, we
estimated the number of DSAs performed based on the
assumption that a DSA would have been performed when a
drop of more than 0.20 in ABI occurred in the first post-
operative year. For clinical follow-up, we estimated the
number of DSAs performed based on the assumption that a
DSA would have been performed when the patient had
symptoms of intermittent claudication or critical limb
ischemia during the first postoperative year.
Costs and clinical outcomes were compared across the
different surveillance programs, and we calculated incre-
mental costs per major amputation avoided during the
first postoperative year compared with the next best pro-
gram for all programs that were not inferior by (extended)
dominance. A program was inferior by dominance when
another program was more effective and less costly, and a
program was inferior by extended dominance when
another program was more effective and had a lower
incremental cost-effectiveness ratio. Effectiveness was
defined in this study as the number of major amputations
avoided per 1000 patients during the first postoperative
year. The fewer major amputations that were performed
under a certain program, the more effective the program
was deemed to be. Incremental cost-effectiveness ratios
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Table I. Costs of interventions for graft failures and pro-
cedures performed in a surveillance program (in 1995
US dollars)
Intervention Costs
Duplex scan examination 91
ABI 37
DSA 271 (868)*
Outpatient visit 15
Angioplasty 2920
Secondary reconstruction 3886
Thrombolysis† 8052
Minor amputation 4652
Major amputation 48,324
Procedure and hospital costs 9162
Rehabilitation 39,162
Nursing home for 2 mo 13,478
Home care for 1 mo 2484
Artificial leg 4037
Rollator 528
Adaptation of home 18,634
*Includes 1 day of hospitalization, used in the sensitivity analysis.
†Costs of thrombolysis were available from the literature.24
were expressed as additional dollars per major amputation
per patient avoided.
For a sensitivity analysis, probabilities extracted from
the article by Brewster et al20 were used to run the simula-
tion model. Also in a one-way sensitivity analysis, we
explored the effect of (1) assuming DSA would be per-
formed as an inpatient procedure (Table I), (2) assuming
that a large proportion of revisions could be planned solely
based on the findings on duplex ultrasound scan (number
of performed DSAs was reduced by 50%), (3) varying the
costs between 50% and 150% of the baseline cost estimates
(Table I), (4) using other values for the relative risks (Table
II), (5) using different cutoff values of the ABI for ABI sur-
veillance (0.15 and 0.25), (6) assuming a higher proportion
of thrombolysis under ABI surveillance and clinical follow-
up (half of the interventions were thrombolyses), (7)
assuming that half the additional major amputations under
ABI surveillance and clinical follow-up were below-knee
amputations and therefore less costly (50% of the baseline
rehabilitation costs), (8) assuming that duplex scan surveil-
lance could have avoided 6 major amputations per 1000
patients treated for intermittent claudication compared with
the other surveillance programs, and (9) varying the num-
ber of outpatient visits with clinical follow-up (ranging from
3 to 5 clinical visits per patient in surveillance).
RESULTS
Clinical study. More than half of the study popula-
tion was male (58.7%), and the mean age of the patients
was 70.1 years. Critical limb ischemia was the presenting
symptom in most patients (73.4%). More detailed infor-
mation on patient characteristics can be found in Table
III. The overall 1-year primary patency rate was 0.64 (SE,
0.03), and the overall 1-year primary assisted patency rate
was 0.87 (SE, 0.02). For patients treated for critical limb
ischemia, these numbers were 0.63 (SE, 0.03) and 0.86
(SE, 0.02), respectively. For patients treated for intermit-
tent claudication, these numbers were 0.66 (SE, 0.05) and
0.88 (SE, 0.04), respectively. More information on
patency rates can be found in the article by Idu et al.9 The
average costs per patient during the first postoperative year
were $2823 (SE, $417). These costs were $2974 (SE,
$504) for patients treated for critical limb ischemia and
$2404 (SE, $724) for patients treated for intermittent
claudication. Four patients (1.9%) treated for critical limb
ischemia needed a major amputation above the knee, com-
pared with one patient (1.3%) treated for intermittent
claudication (Table IV).
In total, 79 patients (27.0%) had one or more inter-
ventions (34 angioplasties, 67 surgical revascularizations,
and 3 thrombolyses). Angioplasty was the first intervention
for 30 patients, and eight patients needed one or more
repeat interventions. Surgical revascularization was the first
intervention for 47 patients, and 13 patients needed one or
more repeat interventions. Two patients had a thromboly-
sis, one of whom needed a repeat thrombolysis, and the
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Fig 1. Scheme of the simulation model. In the simulation model, patients will enter duplex scan surveillance, ankle-brachial index sur-
veillance, and clinical follow-up. Data for duplex scan surveillance were available from the clinical study. Results for ankle-brachial index
surveillance and clinical follow-up were partly based on literature data.
other patient had a repeat surgical revascularization. Of the
104 interventions, 61 (58.7%) were based on duplex scan
criteria only, 1 (1.0%) was based on a drop in ABI only, 1
(1.0%) was based on symptoms only, 11 (10.6%) were
based on both duplex scanning and a drop in ABI, and 3
(2.9%) were based on the combination of duplex scanning,
a drop in ABI, and symptoms. For one intervention, the
data about the surveillance criteria were missing.
Fourteen patients were excluded from the study pop-
ulation because they did not have duplex scan surveillance.
Between 30 days postoperatively and 1-year follow-up,
three of these patients died. Four major amputations
above the knee, six interventions to salvage the graft, and
seven DSAs were performed. The average costs for these
patients were $16,134 (SE, $7,189).
Simulation model. In the total study population of
293 patients, 134 DSAs were performed under the duplex
scan surveillance program, 130 DSAs would have been
performed under the ABI surveillance program, and 51
DSAs would have been performed under clinical follow-
up. For the entire patient population, duplex scan surveil-
lance was the least expensive ($2823) and resulted in the
fewest major amputations (17 per 1000 patients exam-
ined), compared with ABI surveillance ($5411 and 77
major amputations per 1000 patients) and clinical follow-
up ($5072 and 77 major amputations per 1000 patients).
For patients treated for critical limb ischemia, duplex scan
surveillance was the superior surveillance program, result-
ing in the fewest amputations performed (19 per 1000
patients) and the lowest costs ($2974) per patient (Fig 2,
A). Both ABI surveillance and clinical follow-up were infe-
rior by dominance for patients treated for critical limb
ischemia. For patients treated for intermittent claudica-
tion, under all programs, 13 major amputations per 1000
patients were performed, and clinical follow-up was the
least expensive ($1577; Fig 2, B). The mean costs, the
number of major amputations per 1000 patients, and the
incremental cost-effectiveness ratios for the different treat-
ment indications are presented in Table V.
Sensitivity analysis. Neither the assumptions made in
the simulation model nor the parameters used in the simula-
tion model influenced the results found for the total group of
patients or for patients treated for critical limb ischemia. In
each situation, duplex scan surveillance prevented substan-
tially more amputations than other surveillance programs,
leading to lower overall costs. When a different cutoff (0.15)
for a drop in ABI was used, 60 major amputations per 1000
patients would have been performed. The costs under ABI
surveillance ($4758) were lower than in the baseline analysis,
but duplex scan surveillance was still the optimal program for
patients treated for critical limb ischemia. The explanation for
the decrease in major amputations is that the measured drop
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Table II. Outcome of clinical follow-up of infrainguinal graft failures without a surveillance program
Probabilities (range)*
Outcome Critical limb ischemia Intermittent claudication
Baseline analysis
Interventions: surgical revascularization, 0.59 (0.44 to 0.89) 0.67 (0.50 to 1.0)
thrombolyses, and angioplasties
Major amputations 0.30 (0.21)† 0.05‡ (0.11)
Minor amputations 0.34§ (0.17 to 0.91) 0‡
Sensitivity analysis 
No further surgery 0.21 0.62
Interventions: surgical revascularization, 0.31 0.31
thrombolyses, and angioplasties
Primary amputation 0.31 0.05
Intervention followed by amputation 0.13 0.02
Died before further treatment 0.04 0
*Numbers are based on the relative risk calculated from the paper by Bergamini et al,6 and the numbers between brackets were used for the sensitivity analysis.
†The probability used for the baseline analysis was based on the 1-year limb salvage rate available from Bergamini et al.6 In the sensitivity analysis, we used
the probability based on the annual amputation rate calculated from the 5-year limb salvage rate. 
‡No major amputations were performed for patients treated for intermittent claudication in the study by Bergamini et al,6 and therefore, we assumed that
the relative risk was 1.0, and we doubled the risk in a sensitivity analysis.
§We assumed that the relative risk for minor amputations was 2.0 for patients treated for critical limb ischemia, with a range from 1.0 to 5.38 (baseline rel-
ative risk major amputations).
Numbers are based on the probabilities available from the paper by Brewster et al.20
Table III. Patient characteristics (n = 293)
Age (y): mean (range) 70.1 (33 to 97)
Sex (% men) 58.7
Treatment indications: % (n)
Critical limb ischemia 73.4 (215)
Tissue loss 37.2 (109)
Rest pain 36.2 (106)
Intermittent claudication 26.6 (78)
Diabetes mellitus (%) 39.9
Hypertension (%) 31.7
History of smoking (%) 69.6
History of other vascular disease (%) 49.8
in ABI was always between 0.15 and 0.20 among patients
who underwent a major amputation, and thus, with the lower
cutoff, many amputations could have been avoided. The
results were sensitive for the relative risk of major amputations
for patients treated for intermittent claudication. ABI surveil-
lance ($1959 and 13 major amputations per 1000 patients)
was now the optimal program by doubling the relative risk.
Under the assumption that duplex scan surveillance could
have avoided six major amputations per 1000 patients treated
for intermittent claudication compared with ABI surveillance
and clinical follow-up, duplex scan surveillance was cost-effec-
tive at an incremental ratio of $80,708 compared with clini-
cal follow-up, whereas ABI surveillance was dominated (Fig
2, C). By the use of the probabilities available from the arti-
cle by Brewster et al,20 duplex scan surveillance ($2974 and
19 major amputations per 1000 patients) was the optimal
program for patients treated for critical limb ischemia, com-
pared with ABI surveillance ($4710 and 66 major amputa-
tions per 1000 patients) and clinical follow-up ($7357 and
133 major amputations per 1000 patients). For patients
treated for intermittent claudication, ABI surveillance ($1439
and 9 major amputations per 1000 patients) had an incre-
mental cost of $20,936 per major amputation per patient
avoided, compared with clinical follow-up ($1278 and 16
major amputations per 1000 patients), and duplex scan sur-
veillance ($2404 and 13 major amputations per 1000
patients) was dominated by ABI surveillance.
DISCUSSION
The current study shows that duplex scan surveillance
as a means of detecting failing infrainguinal autologous
vein bypass grafts during the first postoperative year is jus-
tified from a cost-effectiveness point of view. In patients
treated for critical limb ischemia, duplex scan surveillance
leads to a reduction in amputations and, consequently,
lower overall costs than other surveillance programs. In
patients treated for intermittent claudication, duplex scan
surveillance was equally effective as the other programs and
yielded higher costs, but if duplex scan surveillance could
have avoided six major amputations per 1000 patients, it
would have been cost-effective at a relatively low incre-
mental cost per major amputation per patient avoided.
A limitation of our study is that we used a simulation
model instead of a randomized controlled trial to compare
the different surveillance programs.21 At the time the study
was initiated, in the early 1990s, duplex scan surveillance was
increasingly being used in clinical practice, although the
effectiveness of such a program had not been proved. It was
not found ethically sound to withhold duplex scan surveil-
lance from patients, because it was thought that surveillance
might be effective and certainly not harmful. We, therefore,
chose to simulate ABI surveillance and clinical follow-up. A
simulation model, however, has limitations because assump-
tions must be made. We have stated these assumptions
explicitly for the reader to judge, and, moreover, we found
that slightly different assumptions did not influence the
results substantially. Furthermore, in the simulation model,
data from the clinical study were integrated with data from
the medical literature to estimate the costs and clinical out-
comes for the clinical follow-up program. A bias could
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Table IV. Observed costs of the duplex scan surveillance program and resource use, including induced costs during 1-year
follow-up
No. of interventional No. of Maximum no. of  Mean cost 
Treatment indication procedures* patients interventions per patient per patient† SE
Critical limb ischemia (n = 215)
Major amputation 4 4 1‡ 899 446
Minor amputation 12 12 1 260 73
Angiography 103 76 5 130 14
Duplex scan examination 735 215 6 311 8
Outpatient visit§ 735 215 6 51 1
Angioplasty 28 26 2 380 72
Surgical revascularization 46 40 3 831 128
Thrombolysis 3 2 2 112 83
Total 2974 504
Intermittent claudication (n = 78)
Major amputation 1 1 1‡ 620 620
Minor amputation 0 0 0 0 –
Angiography 31 22 3 108 22
Duplex scan examination 299 78 6 349 11
Outpatient visit§ 299 78 6 58 2
Angioplasty 6 6 1 225 89
Surgical revascularization 21 14 3 1046 281
Thrombolysis 0 0 0 0 –
Total 2404 724
*Interventional procedures that consisted of treatment of multiple stenoses simultaneously were counted as one procedure. For the patency data, the sever-
est lesion was considered. For the costs data, the total costs of the procedure were considered.
†Costs are 1995 US dollars.
‡Only one limb per patient was considered, and thus, the maximum number of amputations per patient was one.
§Based on the assumption that the number of outpatient visits equals the number of duplex scan examinations.
potentially have been introduced by differences in patient
characteristics between the clinical study and the available lit-
erature data for the clinical follow-up.6 However, comparing
the mean age (70.1 years in this study vs 65 years), percent-
age of male patients (59% in this study vs 63%), and the per-
centage of patients with intermittent claudication (27% in
this study vs 16%), we did not find major differences
between the two studies. A drawback of using the data by
Bergamini et al6 is that their clinical follow-up included some
form of surveillance with noninvasive tests, but this was lim-
ited and not based on a protocol. Follow-up data without
any kind of surveillance are only available from studies pub-
lished in the early 1980s. An example of such a study is the
one by Brewster et al,20 which we used in the sensitivity
analysis. The results of our analysis may be biased because
clinical follow-up without any form of surveillance probably
has a worse prognosis than that based on the data available
from Bergamini et al.6 The implication of this potential bias
would be that duplex scan surveillance could be even more
favorable than what our results suggest.
Another limitation of our study is that the results are
based on a small number of amputations with, as a result,
uncertainty of the estimated cost-effectiveness ratios. This
limitation applies especially to patients treated for intermit-
tent claudication, in which the amputation rate during the
first year was low (13 per 1000 patients). In the baseline
analysis, all surveillance programs were equally effective for
patients treated for intermittent claudication, and clinical
follow-up had the lowest overall costs. A sensitivity analysis,
however, showed that duplex scan surveillance was cost-
effective if six major amputations per 1000 patients treated
for intermittent claudication could have been avoided com-
pared with the other programs. Considering the sensitivity
analysis and taking into account that an amputation of the
limb has a major impact on the patient’s life, we think that
the use of duplex scan surveillance for patients treated for
intermittent claudication is probably justified.
According to the recommendations of the Panel on
“Cost-effectiveness in health and medicine,”22 effectiveness
is ideally measured in quality adjusted life years (QALYs) to
ensure comparability across health care interventions. In our
study, we chose to measure the effectiveness in number of
major amputations avoided during the first postoperative
year. Amputation of the limb has an enormous impact on the
health-related quality of life of the patient.12,13 Thus, duplex
scan surveillance (compared with other surveillance pro-
grams) increases effectiveness, whether expressed as amputa-
tions avoided or QALYs, and decreases costs by the cost-
savings of avoiding amputations. Duplex scan surveillance
did increase the number of graft revisions, but these addi-
tional costs did not outweigh the cost-savings of avoiding
amputations. Overall, duplex scan surveillance is both more
effective and less costly than other surveillance programs,
implying that the estimation of QALYs gained is irrelevant.
For the subgroup treated for intermittent claudication, the
additional cost per amputation avoided found in the sensi-
tivity analysis was reasonable ($80,000). Because a major
amputation avoided will impact health-related quality of life
substantially for the rest of the patient’s life span, this addi-
tional cost per amputation avoided translates to a low cost
per QALY gained. For example, if the difference in quality of
life for an amputation avoided is approximately 0.40 and a
patient has 10 years of life expectancy, then an $80,000 per
amputation avoided translates to $80,000/(0.40 × 10)
QALYs = $20,000/QALY, which is well within the gener-
ally accepted range.
Furthermore, a limitation of our study is that we only
explored the cost-effectiveness of duplex scan surveillance
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Fig. 2. Cost-effectiveness plots for patients treated for tissue loss (A), for patients treated for intermittent claudication (B), and for
patients treated for intermittent claudication assuming that duplex scan surveillance could have avoided six major amputations per 1000
patients compared with the other surveillance programs (sensitivity analysis; C). In all panels, the y-axis represents the average costs per
patient with surveillance during the first postoperative year in 1995 US dollars. The x-axis represents the number of major amputations
per 1000 patients during the first postoperative year and is inverted to be consistent with the usual presentation of cost-effectiveness
plots (ie, effectiveness increases to the right).
during the first postoperative year. We thought it was jus-
tified to focus on the surveillance programs with this lim-
ited time frame, because most infrainguinal vein bypass
graft failures occur within the first postoperative year.23
Surveillance programs beyond the first postoperative year
should be addressed, but they are likely to be very expen-
sive because the failure rate is so much lower. Finally, we
did not address the scheme of surveillance, because this is
generally dictated by what is practically feasible.
In summary, we found that duplex scan surveillance is
highly effective for patients treated for critical limb
ischemia, leading to a reduction of amputations and, con-
sequently, to a reduction in costs compared with other
surveillance programs. For patients treated for intermit-
tent claudication, the evidence supporting duplex scan
surveillance was less firm, but if duplex scan surveillance
can avoid six major amputations per 1000 patients, the
incremental costs are justified. We conclude that duplex
scan surveillance during the first year after infrainguinal
autologous vein bypass grafting surgery is cost-effective.
We thank M. J. M. A. Gulikers and S. Maijoor, PhD,
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Table V. Mean costs and number of major amputations per 1000 patients across various surveillance programs for
infrainguinal autologous vein bypass graft surgery, including induced costs during 1-year follow-up
Critical limb ischemia (n = 215) Intermittent claudication (n = 78)
Surveillance program Mean cost* Major amputations† Incremental cost‡ Mean cost* Major amputations† Incremental cost‡
Duplex scan 2974 19 S 2404 13 D
ABI 6664 100 D 1959 13 D
Clinical follow-up 6340 100 D 1577 13 S
*Costs are 1995 US dollars.
†Major amputations per 1000 patients.
‡Incremental cost per major amputation per patient avoided during the first postoperative year.
D, Inferior by dominance; S, superior, meaning that the strategy is both more effective and less costly than the other strategies.
